Triple-Negative Breast Cancer | Topics

Axillary Ultrasound/Biopsy Effective Identifying Nodal Disease in TNBC at Diagnosis
March 14, 2022

Axillary ultrasound and biopsy appear to be an effective strategy to identify nodal disease in patients with early-stage triple-negative breast cancer.

Parallel Genomic Alterations Associated With Clinical Resistance to Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
January 01, 2022

The study from Cancer Discovery examined a 3-case autopsy series, finding associations between TROP2 absence and limited clinical responses to sacituzumab govitecan for patients with metastatic triple-negative breast cancer.

Utilization of ctDNA Helps to Identify Relapse in Triple-Negative Breast Cancer
December 10, 2021

Circulating tumor DNA should be utilized early to help detect relapse in patients with triple-negative breast cancer.

EFS Improved With Neoadjuvant and Adjuvant Pembrolizumab Across Subgroups of Patients With Early-Stage TNBC
December 08, 2021

Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.

Positive Response Activity Seen With Datopotamab Deruxtecan in Advanced TNBC
December 08, 2021

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.

Treatment with Pembrolizumab/Chemo Combo May Be a Standard of Care in mTNBC
December 07, 2021

Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.

Single-Cell Spatial Analysis for Immunotherapy Response Prediction in Early TNBC Shows Promise
December 07, 2021

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

Adding Carboplatin to Neoadjuvant Paclitaxel Improved Outcomes in TNBC
September 18, 2021

Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.

Atezolizumab TNBC Indication Withdrawn By Manufacturer After Talks With FDA
August 27, 2021

Atezolizumab will no longer be available for the treatment of patients with PD-L1–positive triple-negative breast cancer following withdrawal of the indication by the agent’s developer.

Leronlimab Provides a Significant Survival Benefit in Metastatic Triple-Negative Breast Cancer
August 25, 2021

Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer.